Figma, Inc. (FIG)

The panel's take

Verdict: BALANCED · Conviction: MEDIUM · Last price: USD 23.65 (July 14, 2026)

Figma is caught at an inflection point where the fundamental case is real — 139% NRR, 46% growth, $1.58B net cash, fortress balance sheet — but priced as if the market has already resolved its central uncertainty (whether AI expands or disrupts the design workflow). The panel splits 3 bullish, 2 neutral, 1 bearish. The bulls argue AI expands the addressable surface; the bears argue it disintermediates Figma's moat by making Claude Design a direct retail threat. The consensus is quality at contested valuation — fair price, not a margin-of-safety price, in a macro and competitive headwind environment.

---

Key levels

Resistance: The $31.80 level (200-day MA) is the first structural ceiling; a break and hold would signal a shift from sideways consolidation to a new uptrend. Current price sits under the 50-day and 100-day moving averages, reflecting a lack of momentum — the stock is waiting for either a catalyst (Q3 guidance, Claude Design resilience proof) or a pullback confirmation (test of S2 at $19.50).

Current price: At $23.65, Figma sits in a mid-zone with limited margin of safety — the bull case (AI expands TAM, NRR holds 135%+) is roughly priced in, but the bear case (Claude Design is a moat crack, SBC dilution overstated) is not. Consensus analyst target is ~$30.56 (limited upside), and the panel's fair-value estimates range from $15–17 (bear) to $35–40 (bull).

Support: The 200-day MA at $21.80 is uptrend support; loss would signal a deeper pullback. The $19.50 zone is where value investors see accumulation potential (SBC concerns baked in). Through-cycle fair value sits deeper, near $15–17, if Claude Design proves to be structural headwind rather than temporary competitive noise.

---

What legendary investors think

We ran Figma past a panel of six legendary investors' frameworks.

---

Where they agree — and where they clash

Common ground:

• Quality metrics are genuine — 82% gross margin, 139% NRR, 46% YoY growth, $1.58B net cash, 690K paid customers (+54% YoY) are real quality signals. This is not a broken business.
• The IPO peak at $142.92 was froth — 83% drawdown has eliminated speculative excess.
• AI is the central uncertainty — whether Claude Design/competitors expand or disintermediate the design workflow will shape the next decade of value creation or destruction.
• SBC dilution is material — at 51% of Q1 revenue ($169M SBC on $333M revenue), stock-based compensation is the single largest gap between bull-case consensus price targets and intrinsic valuation when expensed properly.

The real debates:

Debate #1: Does AI Expand or Disintermediate Figma's Moat?

• The Disruptive-Innovation Seeker & The Margin-of-Safety Hunter argue AI expands the addressable surface — non-designers now "make" in Figma via AI-assisted features (Make, Weave). Figma Make WAU +70%, paid customers +54%. TAM grows when new personas buy. NRR sustained at 139% proves the value unit is expanding, not fragmenting.
• The Intrinsic-Value Modeler & The Moat Compounder counter: Anthropic sells Claude Design directly at retail. Figma buys Claude tokens wholesale and marks them up. That's a retailer-to-wholesaler conversion — margin compression embedded in unit economics. CEO selling 174k shares 3 days before Claude Design's launch reads as loss of conviction. The market hasn't priced this structural risk.

Debate #2: Is the Current Price Bullish or Neutral Valuation?

• The GARP Operator sees PEG 0.23–0.87 as screaming buy. Rule of 40 = 62–73 (best-in-class trajectory). Growth is re-accelerating; the market is still cautious. Fair value is higher.
• The Intrinsic-Value Modeler responds: Rule of 40 ignores dilution. When SBC is expensed properly (8–13% terminal, not 51% current), fair value drops to ~$15–17. Current $23.65 embeds the bull-case outcome — limited upside for a story with unresolved, actively deteriorating central uncertainty.

Debate #3: Growth Deceleration or Reacceleration?

• The Disruptive-Innovation Seeker & GARP Operator highlight Q1 FY26 reacceleration (40% → 46% YoY) and raised FY26 guidance (~35%). AI is driving new-persona adoption. Inflection is underway.
• The Macro Opportunist counters: Fed likely holds/hikes (74.9% probability); tech-SaaS sentiment is fragile. Weekly chart shows Death Cross intact. $31.63 (200-day MA) is a 34% overhead hurdle in a macro headwind environment. Earnings aren't the blocker; macro is.

---

The numbers

Metric	Q1 2026	FY2025	Assessment
Revenue	$333.4M (+46% YoY)	~$1.27B	Reaccelerating from 40%; guidance raised to ~35% for FY26
Paid Customers	690K (+54% YoY)	~632K	Logo growth intact; land-and-expand narrative supported
NRR	139%	133%	Best-in-class; trending up, not down. Anchors bull case.
Gross Margin (non-GAAP)	82%	~80%	Structurally strong; SBC is the margin mirage.
Operating Margin (non-GAAP)	16%	~(2%) GAAP	SBC now ~$169M/quarter = 51% of revenue. Expensed GAAP margin closer to 2–3%.
SBC as % of Revenue	~51%	~40% (normalized)	IPO-cliff inflated; consensus assumes 8–13% terminal. KEY VALUATION DRIVER.
Net Cash	$1.58B	$1.64B	Strong balance sheet; no leverage. All-equity story.
Short Interest	42.4% of float	Elevated	Market skeptics present; capitulation squeeze possible or breakdown risk.
P/E (TTM)	~179x	-	Extreme; inflated by post-IPO accounting. Fair value depends entirely on SBC treatment.
Analyst Consensus Target	~$30.56	-	Only +29% upside despite the growth; targets revised but still below $31.63 (resistance).

Figures from Figma Q1 2026 (quarter ended March 31, reported May 7, 2026) / current pricing July 14, 2026; sourced from Figma IR, Investing.com, stockanalysis.com. Through-cycle fair values per investor models: The Intrinsic-Value Modeler ~$15–17, The Margin-of-Safety Hunter & The Disruptive-Innovation Seeker ~$35–40+, The Moat Compounder ~$20–25 (awaiting thesis clarity).

---

The bottom line

Figma at $23.65 is BALANCED — a quality growth story at contested valuation.

Figma is the panel's clearest "the fundamentals are real, but the price reflects bullish assumptions that remain unproven" call. The bull case is compelling: 139% NRR, 46% growth, $1.58B net cash, fortress capital, and AI-driven new-persona adoption (Figma Make WAU +70% q/q, paid customers +54%) paint a picture of a durable, expanding business. The 83% drawdown from IPO peak has cleared froth, and the market's 42.4% short interest suggests despair pricing where quality should trade at a premium. But the panel's caution is equally concrete and, at this price, decisive: the stock trades at ~179x trailing earnings and ~63x forward earnings (extreme even for a 46%-growth SaaS), with every fair-value estimate on the panel ($15–17 bear, $25–35 base, $40+ bull) dependent on a single unresolved assumption: whether Claude Design is a durable threat (bear case) or a temporary competitive noise (bull case) that the NRR holds through. Tellingly, even the two bulls (Disruption, GARP) explicitly want proof, not conviction today — they want to see Q3 NRR resilience or a pullback before adding. What would tip the call bullish: a Q3 earnings print showing NRR holding above 135% after Claude Design's July launch, plus management's explicit repricing of the AI opportunity. What keeps it BALANCED is that absence of that confirmation, buyers are paying for flawless execution in an increasingly crowded AI design layer — where Anthropic's retail distribution and cost structure give them margin advantages Figma can't overcome if the workflow truly disintermediates. The magnitude of the quality metrics (82% gross margin, 46% growth, 139% NRR) and the panel's genuine disagreement (3 bullish, 2 neutral, 1 bearish, all medium conviction) is why this is BALANCED, not SELL — but it's also why this is BALANCED, not BUY, without either proof of AI resilience or a pullback to $19–21 where SBC concerns are better reflected.

This is analysis, not investment advice. Consult a qualified financial advisor before making any investment decisions.

---

Catalyst calendar: July 14 Claude Design launch (passed) · August–September Q2 earnings + guidance (critical NRR read post-Claude) · Q3 earnings (Oct/Nov, thesis validation window)

Next review trigger: Q2/Q3 earnings confirmation, Claude Design adoption data, or technical break of $31.80 resistance

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 23.95 (as of 2026-07-17) · Changed from BALANCED

What changed since 2026-07-14:

• Price: USD 23.65 → 23.95 (+1.3%) — a rally toward the 200-day moving average that stalled just below it.
• Panel: 3 of 6 → 0 of 6 now Bullish (The Disruptive-Innovation Seeker and The GARP Operator both moved from Bullish to Neutral; The Moat Compounder moved from Neutral to Bearish) — the panel also swapped last week's Margin-of-Safety Hunter (Bullish) for a new lens, The Forensic Skeptic (Bearish), so no seat on this week's panel is bullish.
• Trigger: Q2 earnings (August–September) — the print every lens on the panel names as the resolution point for whether Claude Design expands or erodes Figma's surface.
• Verdict: BALANCED → WAIT

Figma's business quality isn't the argument this week — 46% revenue growth and 139% net revenue retention are real, and every panelist says so. What moved the synthesis is timing: no lens is willing to call the stock outright bullish while price stalls at resistance and the market awaits confirmation, but the dissent reads as a call for more data, not a broken thesis — which is why this lands at WAIT rather than SELL.

Key levels

Key resistance sits at USD 30.26 (this week's rejected high, on the heaviest volume of the basing period) and USD 31.80 (the 200-day moving average, the major structural level above it); key support sits at USD 21.80, with a deeper historical accumulation zone near USD 19.50. The analyst consensus target is n/a this week — no fresh figure was cited by the panel.

What legendary investors think

We ran Figma past a panel of six legendary investors' frameworks, continuing the debate from the July 14 analysis.

Where they agree — and where they clash

The question it comes down to: Does Q2 earnings confirm net revenue retention holding near 139% in the face of Claude Design — validating the growth story at a reasonable multiple — or does the stock-comp math mean the reported quality metrics were overstated all along?

The numbers

Metric	Value
Price / Market cap	USD 23.95 / n/a
P/E (TTM / fwd)	181x / 64x
ROE	n/a
Operating margin	~2-3% GAAP (~51% of revenue converts to stock-based compensation)
Dividend yield	n/a
Debt / equity	0x (net cash of USD 1.58B, no debt)
Free cash flow	n/a

Figures as cited by the panel this week (revenue growth, net revenue retention, and customer counts trace to Q1 FY2026 results reported May 2026) and in continuity with the July 14, 2026 analysis; current price and technical levels as of 2026-07-17. Market cap, ROE, dividend yield, and free cash flow were not restated this week — n/a rather than invented.

The bottom line

What would tip the call toward BUY: Q2 earnings (August–September) showing net revenue retention holding near 139% after the Claude Design launch, paired with a reclaim of the USD 27.50–30.26 zone on strong volume. What would tip it toward SELL: net revenue retention deteriorating materially, or the 51%-of-revenue stock-comp load failing to normalize toward its 8–13% terminal range. The Forensic Skeptic's objection is the one to watch most closely — it's currently the lone lens reading the stock-comp figure as evidence the quality metrics were overstated from the start rather than a timing question; if others on the panel start agreeing with that framing before Q2 reports, WAIT could tip to SELL ahead of the earnings date itself. Until then, the panel — like the market — is waiting on one print, not the tape.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 21.12 (as of 2026-07-25)

What changed since 2026-07-18:

• Price: USD 23.95 → 21.12 (−11.8%) — a failed breakout at the USD 24.87–25.76 zone followed by a heavy-volume reversal that broke clean through last week's S1 support (USD 21.80), which now functions as overhead resistance rather than a floor.
• Panel: signal composition unchanged (3 of 6 Bearish, 3 of 6 Neutral, 0 of 6 Bullish) — but conviction intensified among the bears. The Macro Opportunist moved Medium → High, citing the confirmed break of support on heavy volume; The Forensic Skeptic moved toward High on newly reported detail that roughly half of shares outstanding sit behind a rolling 2026 lockup schedule.
• Catalyst: Q2 earnings is now confirmed for August 5, 2026 after market close — down from last week's "six to eight weeks out" to roughly eleven days away.
• New information cutting both ways: on the negative side, an activist investor is publicly pushing Figma to cut its product line and rein in stock-based compensation (now estimated near 27% of 2026 revenue), while three sell-side firms trimmed price targets this month even as their ratings held (Buy/Hold unchanged); on the positive side, Q1 FY2026 results the panel hadn't fully priced last week show revenue growth accelerating to 46%, net revenue retention at a two-year high of 139%, and Figma's first reported positive free cash flow (USD 88.6M, a 27% margin).
• Verdict: WAIT (unchanged).

Nothing this week resolves the question the panel identified on 2026-07-18 — it still comes down to the August 5 print. What moved is the tape and the stakes: price broke the support level the panel was watching, on volume that reads as distribution rather than a shakeout, while the underlying growth and cash-flow numbers that came in during the week actually strengthened. That combination — improving fundamentals, deteriorating chart, tightening catalyst window — is exactly the setup that keeps a call at WAIT rather than tipping it either direction; acting on the chart alone would mean selling into improving quality metrics, and acting on the quality metrics alone would mean buying into a confirmed technical break eleven days before the data that actually settles the debate.

Key levels

The prior article's S1 (USD 21.80) is broken — price has closed at or below it for two straight weeks and it now sits overhead as a pivot to reclaim, not a floor. The nearer resistance is the USD 24.87–25.76 zone, where price has now failed twice; the longer-range structural ceiling near USD 29.39–32.65 is the highest post-crash swing area and sits well above current spot. On the downside, the USD 19.50–19.90 band has held on two separate tests (most recently this week) and is the level to watch first; below that, the USD 16.60–16.80 zone is the structural floor of the entire five-month basing range, and a weekly close beneath it would be the first sign of Stage-4 resumption rather than a pullback within a base.

What legendary investors think

We ran Figma past a panel of six legendary investors' frameworks, continuing the debate from the July 18 analysis.

Where they agree — and where they clash

The question it comes down to: Does the August 5 print confirm net revenue retention holding near 139% with stock comp trending toward its terminal range — validating the growth story at a price that's now materially cheaper than two weeks ago — or does the combination of broken support, a widening lockup overhang, and margin guidance cut to ~9% mean the market has already started pricing in disintermediation ahead of the data?

The numbers

Metric	Value
Price / Market cap	USD 21.12 / ~USD 11.16B
P/E (TTM / fwd)	n/a (GAAP net loss) / ~62–78x
ROE	n/a
Operating margin	~9% non-GAAP guided (full-year, down on AI compute spend); ~51% of revenue still converts to stock-based compensation
Dividend yield	n/a
Debt / equity	0x (net cash of USD 1.58B, no debt — unchanged this week)
Free cash flow	USD 88.6M (27% margin), Q1 FY2026

Price and technical levels as of 2026-07-24/25; market cap, forward P/E, and analyst-target range per stockanalysis.com (2026-07-24) and tradingkey.com (2026-07-22); free cash flow, revenue growth, and net revenue retention trace to Q1 FY2026 results reported 2026-05-14 (Figma investor relations / SEC 8-K), restated this week for the first time as a confirmed figure. ROE and dividend yield not restated — n/a rather than invented.

The bottom line

What would tip the call toward BUY: the August 5 print showing net revenue retention holding near 139% with stock comp genuinely trending toward its terminal range, paired with a reclaim of the broken USD 21.80 pivot on strong volume. What would tip it toward SELL: retention slipping, the ~9% operating-margin guidance proving to be the new normal rather than a transitional dip, or a weekly close below the USD 19.50–19.90 support band that would put the USD 16.60–16.80 structural floor back in play. The gap between this week's chart (confirmed break of support, heavy-volume distribution) and this week's fundamentals (accelerating growth, record retention, first positive free cash flow) is the whole story right now — and with the resolving data eleven days out, the panel sees more value in waiting for it than in trading either signal in isolation.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 24.32 (as of 2026-08-02)

This is a consensus BUY vs WAIT split, not BUY vs SELL. The bulls (The Disruptive-Innovation Seeker, The Scuttlebutt Growth Investor) argue the business is exceptional — dominant moat, 40%+ revenue growth, 139% NDR, $1.6B net cash. The cautious camp (The Intrinsic-Value Modeler, The GARP Operator, The Structural Tailwind Rider) overwhelmingly agrees the business is high-quality but objects on price/timing: PEG ~3.5, forward P/E ~80x, no margin of safety at $24. Only The Forensic Skeptic objects on business grounds (structural SBC dilution), and he is a lone dissenter. The structure demands WAIT — great business, wrong price — not HOLD, because the objection is overwhelmingly price-driven and the identifiable trigger (USD 32.65 breakout or USD 16–18 pullback) is clearly articulated by multiple voices.

Key levels

Price sits below key resistance at USD 32.65, 40.28, and 43.63, with key support at USD 21.86, 19.85, and 16.60 beneath it; no analyst consensus target was available at the time of publication.

What legendary investors think

We ran Figma, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Will Figma's AI platform pivot expand its addressable market fast enough to justify an 80x forward earnings multiple before revenue-growth deceleration compresses that multiple first?

The numbers

Metric	Value
Price / Market cap	USD 24.32 / ~USD 12B
P/E (TTM / fwd)	-8.2x (GAAP, loss-making) / ~80.5x (non-GAAP)
ROE	~-100% (LTM GAAP)
Operating margin	n/a
Dividend yield	n/a
Debt / equity	0.00 (net cash)
Free cash flow	USD 237M (LTM)

Figures as of Jul 28, 2026 (LTM through Q1 2026 / FY2025); sourced from Trefis (trefis.com/data/companies/fig) and ainvest.com. Market cap reflects the source snapshot's ~$22.90 close (Jul 28, 2026), a few points below this article's Aug 2 price.

The bottom line

The next identifiable catalyst is Q2 2026 earnings expected in late August — revenue above $350M with raised full-year guidance would strengthen the Disruptive-Innovation Seeker's AI-monetization thesis, while growth below 20% would validate the Forensic Skeptic's structural-concern view. The SBC-to-revenue ratio in the next 10-Q is the single most important number to watch: if it trends below 80% from the current ~90%+ run rate, the dilution argument weakens materially; if it rises, even the bulls' conviction should fade. A decisive weekly close above USD 32.65 with expanding volume would confirm the double-bottom base and shift the call to BUY by signaling the end of the post-IPO downtrend, while a pullback into the USD 16–18 zone that holds would bring the forward PEG close to 1.5 and satisfy the margin-of-safety condition that currently divides the panel. A weekly close below USD 16.60 would invalidate the base and open the path toward the Forensic Skeptic's $15 intrinsic value estimate.

The panel's take

Verdict: WAIT · Conviction: HIGH · Last price: 23.29

What changed since 2026-08-02:

• Price: 24.32 → 23.29 (-4.24%)
• Panel: 2 of 6 → 1 of 6 now Bullish — composition also changed: added The Quality Rationalist; removed The Structural Tailwind Rider
• Trigger: BUY on: (a) weekly close above $32.65 on volume — confirms the Stage 1→2 transition, or (b) pullback to $17–18 (7× sales) paired with evidence SBC dilution is moderating. SELL on: weekly close below $19.85 — base failure signal — or revenue growth decelerating below 25% without SBC moderation.
• Verdict: WAIT (unchanged)

The stock drifted ~4% lower since the prior article while The Quality Rationalist replaced a growth-oriented voice on the panel, hardening the price/timing objection. With no new data on whether SBC dilution is moderating and the stock still trapped between $19.85 and $32.65, conviction in the WAIT rises to HIGH: the business quality is undisputed, the price objection is unanimous among cautious voices, and the concrete triggers in both directions remain unchanged.

BUY vs WAIT split: The Disruptive-Innovation Seeker's bullish AI S-curve thesis is credible, but every cautious voice, from The Intrinsic-Value Modeler to The Quality Rationalist to the technical scout, agrees Figma is a high-quality business they simply won't pay today's price for. Value-oriented voices want $15–18; momentum voices want confirmation above $32.65. The stock sits in no-man's land where neither camp is satisfied. WAIT, not HOLD, because price/timing is the single blocker and concrete triggers exist in both directions.

Key levels

What legendary investors think

We ran Figma, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Can Figma's AI monetization accelerate fast enough to outrun the dilution that's silently destroying per-share value, or will the SBC tax catch up to the growth story before the S-curve kicks in?

The bottom line

• Trigger to confirm the breakout: A weekly close above $32.65 on elevated volume, confirming the Stage 1→2 transition and signaling the market is finally pricing in the AI S-curve thesis rather than fighting it.
• Pullback that would draw in value interest: A decline to $17–18 (roughly 7× sales), paired with quarterly evidence that SBC as a percentage of revenue is declining, would bring the value-oriented frameworks off the sidelines.
• Risk to monitor: A weekly close below $19.85 would break the basing structure and open the door to a retest of the $16.60 low, a base-failure signal that invalidates the accumulation thesis.
• Next catalyst: Q3 earnings (expected November 2026): the critical datapoint is whether revenue growth holds above 30% while SBC dilution shows meaningful moderation, or whether AI credit adoption stalls.
• Further out: Watch for a formal SBC reduction plan targeting below 20% of revenue, or the initiation of a share buyback program. Either would signal management is finally prioritizing per-share value over raw growth.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 25.42

What changed since 2026-08-08:

• Price: 23.29 → 25.42 (+9.15%)
• Panel: 1 of 6 → 1 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer, The Margin-of-Safety Hunter; removed The Quality Rationalist, The Scuttlebutt Growth Investor
• Trigger: Flip to BUY on: (1) a pullback into the $18-22 range where P/S compresses to 6-7x and FCF yield approaches 3.5-4%, providing actual margin of safety; OR (2) a weekly close above $30.33 on expanding volume confirming the base resolves higher, paired with a GAAP profitability inflection or meaningful SBC moderation. Flip to SELL on: a weekly close below $16.60 (invalidating the basing thesis) OR FCF margins compressing below 15% coupled with revenue growth decelerating below 15%.
• Verdict: WAIT (unchanged)

Since the prior article (August 2026, $23.29, WAIT/HIGH conviction), the stock has rallied 9% and two frameworks rotated onto the panel — The Asymmetric Bargainer and The Margin-of-Safety Hunter — both of whom object on price or principle rather than business quality. The WAIT verdict holds not because the story weakened, but because the rally tightened the valuation vise: the intrinsic-value gap remains 26-37%, and the new voices reinforce that the premium today is still too rich for a margin of safety, even as the AI narrative grows louder.

The split is structurally BUY vs WAIT, not BUY vs SELL. Both bulls (The Disruptive-Innovation Seeker) and the price/timing objectors (The GARP Operator, The Asymmetric Bargainer, technical-scout) agree Figma is a high-quality business with a fortress balance sheet, network-effect moat, and accelerating revenue growth. The disagreement is entirely about entry price — bulls see an AI S-curve that justifies today's premium; everyone else sees a great company trading 37%+ above intrinsic value ($18-20 range) with no margin of safety. With zero voices making a genuine BUSINESS objection beyond Ben The Margin-of-Safety Hunter (who disqualifies on principle, not on deteriorating fundamentals), and the two genuine fundamental bears (The Forensic Skeptic, The Margin-of-Safety Hunter) largely echoing overvaluation rather than business decay, the panel tilts WAIT — not BALANCED — because the single blocker is price, and identifiable triggers exist (pullback to $18-22 or a weekly close above $30.33 on volume).

Key levels

What legendary investors think

We ran Figma, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Can Figma convert three quarters of AI-driven revenue acceleration into durable, per-share earnings growth before the multiple compresses to reflect the SBC and dilution reality that the shorts are already pricing in?

The bottom line

• Key support to watch: A pullback into the $18-22 range would compress P/S to 6-7x and lift FCF yield toward 3.5-4%, putting the stock in the accumulation zone that four of the six frameworks cited as their bullish trigger.
• Breakout confirmation level: A weekly close above $30.33 on expanding volume would resolve the basing pattern to the upside and signal that the AI S-curve thesis is gaining institutional conviction, per the GARP Operator's technical framework.
• Critical risk line: A weekly close below $16.60 would invalidate the entire basing thesis and signal a resumption of the Stage 4 decline, flipping the asymmetry decisively negative across all frameworks.
• Next catalyst: The Q3 2026 earnings report will test whether the three-quarter acceleration claim sustains: revenue growth above 35% YoY paired with a measurable moderation in SBC as a percentage of revenue would directly challenge the bear case.
• The GAAP inflection milestone: A single quarter of positive GAAP net income — even modest — would neutralize the Margin-of-Safety Hunter's core objection and force a re-rating across the entire panel, since it would signal the dilution cycle is maturing.

The panel's take

Verdict: BALANCED · Conviction: MEDIUM · Last price: 27.1 · Changed from WAIT

Panel: 1 Bullish · 4 Neutral · 1 Bearish → BALANCED

What changed since 2026-08-15:

• Price: 25.42 → 27.1 (+6.61%)
• Panel: 1 of 6 → 1 of 6 now Bullish — composition also changed: added The Activist Catalyst, The Scuttlebutt Growth Investor; removed The Asymmetric Bargainer, The Margin-of-Safety Hunter
• Trigger: The prior WAIT trigger stands unfired — price sits between the $18–22 pullback zone and the $30.33 upside breakout. Flip to BUY on a weekly close above $29.25 (78.6% Fib) on expanding volume, the nearest test of whether the basing phase is resolving higher. Flip to SELL on a weekly close below $21.86 (volume POC), which would invalidate the recovery structure and put the $16.60 lows back in play.
• Verdict: WAIT → BALANCED

Figma delivered exactly what bulls needed (AI credits live, third straight quarter of accelerating growth) but failed to deliver what the valuation demands: a catalyst that rewrites the growth trajectory convincingly enough to justify 11.3x sales. The stock's modest rise stayed inside the no-man's-land between the value-entry zone and the breakout trigger, so the panel's neutral majority held firm — the business quality is not in question, only whether the price has already absorbed it.

Four of six panelists land Neutral: the business is exceptional — 43% revenue growth, 136% NDR, $1.6B net cash, and AI monetization is now live — but at 11.3x sales and 55x EV/FCF the valuation prices in flawless execution with no margin of safety. The lone bull (The Disruptive-Innovation Seeker) sees the AI-platform thesis and 34.8% short interest as an asymmetric setup; the lone bear (The Intrinsic-Value Modeler) computes intrinsic value at $18, arguing the market has already paid for the beat rate. At $27.10, upside to the $30.80 consensus target (+14%) and downside to the $25 low target (–6%) are roughly symmetric, so the panel holds. The prior WAIT trigger is not fired: price moved from $25.42 to $27.10 without entering the $18–22 pullback zone or closing above $30.33 with a GAAP inflection.

Key levels

Key resistance at $29.25 is the 78.6% Fibonacci retracement of the $75.70→$16.60 decline — the first overhead test, 8% above price, where counter-trend bounces commonly stall. Above that, $32.65 is weekly horizontal resistance and $39.18 marks the 61.8% retracement. Key support at $21.86 is the volume profile POC — the highest-volume price node of the entire basing period; a break below it would invalidate the recovery. The analyst consensus target of $30.80 sits just beyond the first resistance band, 14% above the current price.

What legendary investors think

We ran Figma, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Will Figma's AI monetization scale fast enough to outrun the multiple compression that hits every high-growth SaaS stock once revenue growth decelerates below 30%, or does the 34.8% short float correctly price the risk that AI tools bypass design-fidelity platforms entirely?

The bottom line

• Breakout confirmation: A weekly close above $29.25 (the 78.6% Fibonacci retracement) on expanding volume would flip the call to BUY by confirming the basing phase is resolving higher.
• Risk to the floor: A weekly close below $21.86 (volume POC) would invalidate the recovery structure, flip to SELL, and put the $16.60 lows back in play.
• Next catalyst: Q3 2026 earnings (late October) will deliver the second full quarter of AI credit monetization data — another beat with accelerating AI-driven revenue would test the short thesis directly.
• Governance trigger: A GAAP profitability roadmap or a buyback announcement from management would address the two most cited concerns across the panel (SBC dilution and idle cash), potentially pulling in the four neutral voters.